Take action in the face of growing resistance

This website is developed and fully funded by Gilead Sciences Europe Limited

I am... associated with low resistance1-5

After more than 50 years of clinical use acquired resistance to amphotericin B, the active ingredient in AmBisome®, has rarely been reported.2-5

There is growing resistance to azoles and echinocandins amongst life-threatening IFI-causing fungal species (spp.), including Candida spp. and Aspergillus spp.2,6-8

Antifungal resistance differs between regions, countries and even hospitals, therefore, it is imperative to stay informed and keep track of resistance in your area8-11

Azole-resistant Aspergillus infections are in danger of becoming a global health threat12

Global azole resistance prevalence in Aspergillus fumigatus * Click your country below to discover local rates of azole resistance10

*Only publications with more than 50 isolates tested are reported.10
**Data includes China, India, Iran, Japan, Kuwait and Pakistan only.

Drug resistance in other fungal pathogens

A high mortality rate of 50–100% is associated with culture-positive azole-resistant invasive aspergillosis13

There is an increase in multi-drug resistant infections due to Candida glabrata, and the globally-emerging pathogen Candida auris.7,8,11,14,15

99.8% of clinical isolates of Candida albicans remained sensitive to amphotericin B in a 2012 study†16

Mucorales are resistant to some azoles and largely show moderate in vitro resistance to echinocandins17

†Study conducted in 9,252 clinical isolates of Candida albicans.16

An international expert panel recommended switching from voriconazole to AmBisome® in confirmed invasive pulmonary aspergillosis caused by an azole-resistant Aspergillus‡12

The ability of the active ingredient of AmBisome® (amphotericin B) to induce fungal cell death by binding to a physiologically important lipid helps it evade resistance18,19

‡International panel of 21 experts (paediatric infectious diseases physicians, pulmonary physicians, medical microbiologists, clinical pharmacologists and haematologists) from 11 countries including Canada, the United States, India, Australia, Japan, and six European countries.12

With low acquired resistance, AmBisome® is ready to help you take on IFIs with confidence in the constantly evolving landscape of fungal pathogens1-5,20-24

Dive into more data with our interactive gallery

View the gallery

USA: United States of America

References:

  1. Messer SA et al. Diagn Microbiol Infect Dis. 2020;97:115007.
  2. Nett JE and Andes DR. Infect Dis Clin North Am. 2016;30:51–83.
  3. Mesa-Arango AC 2012et al. Front Microbiol. 2012;3:286.
  4. Vallejo C et al. Rev Esp Quimioter. 2013;26(4):378–386.
  5. Vincent BM et al. PLoS Biol. 2013;11(10):e1001692
  6. Arendrup MC. Clin Mincrobiol Infect. 2014;20(Suppl. 6):42–48.
  7. Pristov KE & Ghannoum MA. Clin Microbiol Infect. 2019;25:792e798.
  8. Hendrickson JA et al. Curr Infect Dis Rep. 2019;21:47.
  9. Perlin DS et al. Ann N Y Acad Sci. 2015 Sep; 1354(1): 1–11.
  10. Rivero-Menendez O et al. J Fungi (Basel). 2016;4;2(3):21.
  11. Wiederhold NP. Infect Drug Resist. 2017:10 249–259.
  12. Verweij PE. Drug Resist Updat. 2015;21–22:30–40.
  13. Verweij PE et al. Clin Infect Dis. 2016;62(3):362–368.
  14. Alexander BD et al. Clin Infect Dis. 2013;56(12):1724–3.
  15. Perlin DS et al. Lancet Infect Dis. 2017;17: e383–92.
  16. Pfaller MA et al. J Clin Microbiol. 2012;50(6):2040–2046.
  17. ECMM/MSGERC. Cornely OA t al. Lancet Infect Dis. 2019;19:e405–e421.
  18. Gray KC, et al. Proc Natl Acad Sci USA. 2012;14;109(7):2234–2239.
  19. Davis SA et al. Nat Chem Biol. 2015;11:481–487.
  20. Lamoth F et al. Clin Infect Dis. 2017;64(11):1619–21.
  21. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
  22. Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587–2590.
  23. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
  24. AmBisome® Summary of Product Characteristics (UK). Available at: https://www.medicines.org.uk/emc/product/1022/smpc#gref. Last accessed: April 2022.

Job code: IHQ-AMB-0534
Date of Preparation: April 2022